Gynecologic Cancers

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking adavosertib.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable gynecologic cancer treatment.

Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing emotional support.

The FDA approved bevacizumab-nwgd across several gastrointestinal, gynecological, brain, and lung cancer types.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously treated CCGC.

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.

Lunresertib plus camonsertib showed promising efficacy in advanced endometrial and platinum-resistant ovarian cancers, with ORRs of 25.9% and 37.5%, respectively.

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

Pelvic transposition may improve quality of life and preserve fertility in patients with gynecologic cancer undergoing pelvic radiation.

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.

Patients with Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer, tended to respond to therapy with TORL-1-23

Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.

Bintrafusp alfa induced responses in recurrent/metastatic cervical cancer, supporting the need for further research into TGF-β-targeted therapies.

Adding IMNN-001 to perioperative chemotherapy enhanced overall survival in patients with newly diagnosed, advanced ovarian cancer.

A dostarlimab-gxly combination was approved for advanced or recurrent endometrial cancer.

Adding dostarlimab to chemotherapy improved survival vs chemo alone in primary advanced or recurrent endometrial cancer.

An expert explores the complexities of immunotherapy during pregnancy, highlighting risks to the fetus and the crucial role of oncology nurses in patient education and management.

Alpha-emitting radiopharmaceutical Radspherin receives a fast track designation from the FDA for peritoneal carcinomatosis from ovarian cancer.

A durvalumab-based combination followed by an olaparib-based maintenance therapy improved progression-free survival in newly diagnosed advanced ovarian cancer without BRCA1/2 mutations.

Progression-free survival and platinum chemoresistance may be predicted by tumor-stroma proportion in patients with high-grade serous ovarian cancer.

Frontline durvalumab plus chemotherapy, followed by maintenance durvalumab with or without olaparib improved responses in stage III/IV or recurrent endometrial cancer.

Throughout June, the FDA approved drugs for the treatment of diseases including myelodysplastic syndrome, thyroid cancer, endometrial cancer, colorectal cancer, and follicular lymphoma.

The approval of this pembro-chemo combination for adults with primary advanced or recurrent endometrial carcinoma includes those with mismatch repair-proficient or -deficient disease.